<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529293</url>
  </required_header>
  <id_info>
    <org_study_id>BC3-CT012</org_study_id>
    <nct_id>NCT02529293</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product and U-200 Product in Healthy Volunteers</brief_title>
  <official_title>A Pilot Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product (2 Single Doses of 0.2 U/kg) and U-200 Product (2 Single Doses of 0.2 U/kg) in Healthy Male and Female</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blinded, randomised, single-centre phase I pilot trial for exploring the
      feasibility of a pivotal clinical trial establishing bioequivalence between BioChaperone
      insulin lispro U-200 and BioChaperone insulin lispro U-100 in healthy subjects.

      Each subject will be randomly allocated to a sequence of four treatments, i.e. two single
      doses of BioChaperone insulin lispro U-200 of 0.2 U·kg BW-1 and two single doses of
      BioChaperone insulin lispro U-100 of 0.2 U·kg BW-1 on four separate dosing visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCLisp (0-inf)</measure>
    <time_frame>8 hours</time_frame>
    <description>Area under the insulin lispro serum concentration - time curve from t=0 to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax Lisp</measure>
    <time_frame>8 hours</time_frame>
    <description>Maximum observed insulin lispro serum concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax Lisp</measure>
    <time_frame>8 hours</time_frame>
    <description>Time to maximum observed serum insulin lispro concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCGIR(0-8h)</measure>
    <time_frame>8 hours</time_frame>
    <description>Area under the glucose infusion rate-time curve from t=0 to 8 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIRmax</measure>
    <time_frame>8 hours</time_frame>
    <description>Maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tGIRmax</measure>
    <time_frame>8 hours</time_frame>
    <description>Time to maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse events</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerability</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Record of injection site reaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BioChaperone Lispro U-100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection of 2 doses of 0.2 U/kg on separate visits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioChaperone Lispro U-200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of 2 doses of 0.2 U/kg on separate visits</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone Lispro U-100</intervention_name>
    <description>Injection of BioChaperone Lispro U-100</description>
    <arm_group_label>BioChaperone Lispro U-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone Lispro U-200</intervention_name>
    <description>Injection of BioChaperone Lispro U-200</description>
    <arm_group_label>BioChaperone Lispro U-200</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, considered generally healthy upon completion of medical
             history, physical examination and biochemical investigations as judged by the
             Investigator.

          -  Age ≥ 18 and ≤ 64 years, both inclusive.

          -  Body Mass Index (BMI) between 18.5 and 28.0 kg∙m-2, both inclusive.

          -  Fasting Plasma Glucose (FPG) ≤ 5.6 mmol/L (100 mg/dL).

          -  Signed and dated informed consent obtained before any trial-related activities, i.e.
             any procedures that would not have been performed during normal management of the
             subject).

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial product(s) or related products.

          -  Receipt of any investigational medicinal product within 3 months before randomisation
             in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grit Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut Für Stoffwechselfforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2015</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

